ATE537185T1 - Vm23 und vm24, zwei skorpionpeptide, die humane t-lymphozyten-kaliumkanäle (untertyp kv1.3) mit hoher selektivität blockieren - Google Patents

Vm23 und vm24, zwei skorpionpeptide, die humane t-lymphozyten-kaliumkanäle (untertyp kv1.3) mit hoher selektivität blockieren

Info

Publication number
ATE537185T1
ATE537185T1 AT07734817T AT07734817T ATE537185T1 AT E537185 T1 ATE537185 T1 AT E537185T1 AT 07734817 T AT07734817 T AT 07734817T AT 07734817 T AT07734817 T AT 07734817T AT E537185 T1 ATE537185 T1 AT E537185T1
Authority
AT
Austria
Prior art keywords
potassium channels
peptides
channels
disclosed
methods
Prior art date
Application number
AT07734817T
Other languages
English (en)
Inventor
Postay Lourival Possani
Georgina Gurrola-Briones
Saida Patricia Salas-Castillo
Batista Cesar Vicente Ferreira
Zoltan Varga
Gyoergy Panyi
Rezsoe Gaspar
Original Assignee
Univ Mexico Nacional Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nacional Autonoma filed Critical Univ Mexico Nacional Autonoma
Application granted granted Critical
Publication of ATE537185T1 publication Critical patent/ATE537185T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
AT07734817T 2007-05-14 2007-05-14 Vm23 und vm24, zwei skorpionpeptide, die humane t-lymphozyten-kaliumkanäle (untertyp kv1.3) mit hoher selektivität blockieren ATE537185T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2007/001544 WO2008139243A1 (en) 2007-05-14 2007-05-14 Vm23 and vm24, two scorpion peptides that block human t-lymphocyte potassium channels (sub-type kv1.3) with high selectivity and decrease the in vivo dth-responses in rats

Publications (1)

Publication Number Publication Date
ATE537185T1 true ATE537185T1 (de) 2011-12-15

Family

ID=38882810

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07734817T ATE537185T1 (de) 2007-05-14 2007-05-14 Vm23 und vm24, zwei skorpionpeptide, die humane t-lymphozyten-kaliumkanäle (untertyp kv1.3) mit hoher selektivität blockieren

Country Status (17)

Country Link
US (1) US8394770B2 (de)
EP (1) EP2158213B1 (de)
JP (1) JP5249319B2 (de)
KR (1) KR101524517B1 (de)
CN (1) CN101796069B (de)
AT (1) ATE537185T1 (de)
AU (1) AU2007353147B2 (de)
BR (1) BRPI0721664A8 (de)
CA (1) CA2686216C (de)
DK (1) DK2158213T3 (de)
EA (1) EA020131B1 (de)
ES (1) ES2379500T3 (de)
IL (1) IL202113A (de)
MX (1) MX2009012092A (de)
PT (1) PT2158213E (de)
WO (1) WO2008139243A1 (de)
ZA (1) ZA200907909B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931806B1 (de) 2005-10-07 2011-10-05 California Institute Of Technology Pkr-aktivierung mittels hybridisierungskettenreaktion
WO2008144562A1 (en) 2007-05-16 2008-11-27 California Institute Of Technology A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
EP2229473A4 (de) 2007-12-07 2011-02-02 Steven A Goldstein Identifizierung von toxinliganden
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
US9834439B2 (en) 2010-07-20 2017-12-05 California Institute Of Technology Biomolecular self-assembly
US8924325B1 (en) * 2011-02-08 2014-12-30 Lockheed Martin Corporation Computerized target hostility determination and countermeasure
US9856472B2 (en) 2013-07-01 2018-01-02 California Institute Of Technology Small conditional RNAs
GB201408135D0 (en) * 2014-05-08 2014-06-25 Conogenetix Biosciences Gmbh Kv1.3 potassium channel antagonists
US10246496B2 (en) * 2014-08-15 2019-04-02 La Trobe University Potassium channel blockers and use thereof in the treatment of autoimmune diseases
WO2018009463A2 (en) 2016-07-05 2018-01-11 California Institute Of Technology Fractional initiator hybridization chain reaction
US10815519B2 (en) 2016-08-30 2020-10-27 California Institute Of Technology Immunohistochemistry via hybridization chain reaction
CN110357950B (zh) * 2019-07-29 2023-04-25 武汉大学 酸性氨基酸扫描法设计的免疫抑制多肽及应用
US11873485B2 (en) 2021-01-26 2024-01-16 California Institute Of Technology Allosteric conditional guide RNAs for cell-selective regulation of CRISPR/Cas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494895A (en) * 1993-07-22 1996-02-27 Merck & Co., Inc. Scorpion peptide margatoxin with immunosuppressant activity
WO1998029446A1 (fr) * 1996-12-26 1998-07-09 Suntory Limited Neuropeptides provenant du scorpion
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents

Also Published As

Publication number Publication date
MX2009012092A (es) 2010-02-12
EP2158213B1 (de) 2011-12-14
IL202113A (en) 2013-01-31
JP5249319B2 (ja) 2013-07-31
EP2158213A1 (de) 2010-03-03
EA020131B1 (ru) 2014-08-29
EA200901530A1 (ru) 2011-08-30
PT2158213E (pt) 2012-03-27
KR101524517B1 (ko) 2015-06-10
CN101796069A (zh) 2010-08-04
BRPI0721664A8 (pt) 2019-01-22
DK2158213T3 (da) 2012-04-10
US8394770B2 (en) 2013-03-12
BRPI0721664A2 (pt) 2013-01-22
WO2008139243A1 (en) 2008-11-20
US20110059064A1 (en) 2011-03-10
JP2010528988A (ja) 2010-08-26
IL202113A0 (en) 2010-06-16
AU2007353147B2 (en) 2014-04-03
CN101796069B (zh) 2014-02-19
CA2686216A1 (en) 2008-11-20
ES2379500T3 (es) 2012-04-26
AU2007353147A1 (en) 2008-11-20
ZA200907909B (en) 2010-07-28
KR20100023867A (ko) 2010-03-04
CA2686216C (en) 2016-04-12

Similar Documents

Publication Publication Date Title
ATE537185T1 (de) Vm23 und vm24, zwei skorpionpeptide, die humane t-lymphozyten-kaliumkanäle (untertyp kv1.3) mit hoher selektivität blockieren
Salvino et al. Design of potent non-peptide competitive antagonists of the human bradykinin B2 receptor
JP2017537893A5 (de)
Loughnan et al. Identification of a novel class of nicotinic receptor antagonists: dimeric conotoxins VxXIIA, VxXIIB, and VxXIIC from Conus vexillum
Konno et al. Crotalphine, a novel potent analgesic peptide from the venom of the South American rattlesnake Crotalus durissus terrificus
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
WO2004066932A3 (en) Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
PE20100684A1 (es) Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh
BRPI0409136A (pt) composto heteroaromático pentacìclico e uso medicinal do mesmo
BRPI0511982A (pt) compostos antiviróticos heterocìclicos
BRPI0617436B8 (pt) derivado heterocíclico fundido, composição farmacêutica compreendendo o mesmo e usos do dito derivado na prevenção ou tratamento de doença dependente de hormônio sexual e na regulação da reprodução, contracepção ou indução de ovulação
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
GT200800189A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
MA28041A1 (fr) Molecules de liaison therapeutiques
WO2007054257A3 (en) Indene derivatives, their preparation and use as medicaments
JP2011523935A5 (de)
RU2016130108A (ru) Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью
ZA200408456B (en) Motif-grafted hybrid polypeptides and uses thereof
AU2021205415A8 (en) Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists
López‐Vera et al. Novel α‐conotoxins from Conus spurius and the α‐conotoxin EI share high‐affinity potentiation and low‐affinity inhibition of nicotinic acetylcholine receptors
BR0313043A (pt) Conjugados efetores, processo para sua produção e seu uso farmacêutico
BRPI0409928A8 (pt) compostos, enantiômeros, composição farmacêutica, uso de compostos, processo para a fabricação de compostos, e, modificação dos processos
BR112018008117A2 (pt) peptídeo cíclico, suporte para cromatografia de afinidade, anticorpo marcado, conjugado fármaco-anticorpo e preparado farmacêutico
KR960702476A (ko) Lhrh 길항제(lhrh antagonists)